644982-65-0

Upstream product

• 878130-44-0 4-(3-fluoro-phenyl)-4-(2-oxo-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 644982-64-9 1,1-dimethylethyl 4-[1-cyano-2-(ethyloxy)-2-oxoethyl]-4-(3-fluorophenyl)-1-piperidinecarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 878130-37-1 4-cyanomethyl-4-(3-fluoro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 17318-03-5 bromo(3-fluorophenyl)magnesium 
• 917220-88-3 4-(carboxy-cyano-methyl)-4-(3-fluoro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 193537-11-0 tert-butyl 4-(1-cyano-2-ethoxy-2-oxoethylidene)-4-piperidine-1-carboxylate 

Downstream Products

• 1014703-33-3 C₂₀H₂₉FN₂O₄ 
• 644982-83-2 1,1-dimethylethyl 4-{2-[[(3,5-dibromophenyl)methyl](methyl)amino]-2-oxoethyl}-4-(3-fluorophenyl)-1-piperidinecarboxylate 
• 1014703-34-4 C₁₉H₂₆FNO₃ 
• 1014703-36-6 C₂₇H₃₆FN₅O 
• 1014703-41-3 C₂₈H₃₈FN₅O 
• 1014702-44-3 (4,6-dimethyl-pyrimidin-5-yl)-{5-[3-(3-fluoro-phenyl)-3-(1-methanesulfonyl-piperidin-4-yl)-1-methyl-propyl]-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl}-methanone 
• 1014702-43-2 (4,6-dimethyl-pyrimidin-5-yl)-(5-{2-[4-(3-fluoro-phenyl)-1-methanesulfonyl-piperidin-4-yl]-1-methyl-ethyl}-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-methanone 
• 1014703-35-5 C₃₂H₄₄FN₅O₃ 
• 1014703-40-2 C₃₃H₄₆FN₅O₃ 

Relevant academic research and scientific papers

A new synthesis of spiropyrrolidine-tetralones via an unexpected formal ring-contraction of 4-disubstituted piperidine to 3-disubstituted pyrrolidine

We have developed an efficient synthesis of novel racemic spiropyrrolidine-tetralones via an unexpected ring-contraction reaction of a 4-disubstituted piperidine to 3-disubstituted pyrrolidine. We suggest that intramolecular quaternization of the piperidi

OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS

Chemokine receptor antagonists, in particular, 3,7-diazabicyclo [3.3.0] octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula (I).

CHEMICAL COMPOUNDS

The present invention relates to cyclic amine derivatives of formula(I) (I)whereinR represents halogen, C1-4 alkyl, cyano, C1-4 alkoxy, trifluoromethyl or trifluoromethoxy;R1 represents hydrogen, halogen, C3-7cycloalkyl, hydroxy, nitro, cyano or C1-4 alkyl optionally substituted by halogen, cyano or C1-4 alkoxy;R2 represents hydrogen or C1-4 alkyl;R3 and R4 independently represent hydrogen, cyano, C1-4 alkyl or R3 together with R4 represents C3-7 cycloalkyl;R5 represents trifluoromethyl, S(O)t C 1-4 alkyl, C1-4 alkyl, C1-4 alkoxy, trifluoromethoxy, halogen or cyano;R6 represents hydrogen or (CH2)rR7;R7 represents hydrogen, C3-7 cycloalkyl, NH(C1-4alkylOC1-4alkoxy), NH(C1-4alkyl), N(C1-4alkyl)2, OC(O)NR9R8, NR8C(O)R9 or C(O)NR9R8;R9 and R8 independently represent hydrogen, C1-4 alkyl or C3-7 cycloalkyl; m represents zero or an integer from 1 to 4;n represents 1 or 2;p is zero or an integer from 1 to 3;q is an integer from 1 to 3;r is an integer from 1 to 4;t is 0, 1 or 2;provided that when m is 0, p is 2, q, r and n represent 1, R1, R2,R3, R4, R5 and R7 are hydrogen and R is chlorine, R5 is not iodine; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of serotonin reuptake transporter protein.